Patent intelligence · US
US 9108918
Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate
Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermed…
Patent details — US 9108918
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 18, 2015
- Expiration
- Aug 13, 2035
- Applicant
- Almirall, S.A.
- Claims
- 26
- CPC classes
- A61K, A61K31/4704, A61P, A61P11/00
Quick answer
US 9108918 (Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate) is held by Almirall, S.A.. Status: granted. Granted Aug 18, 2015. Expires Aug 13, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Almirall, S.A.
- Grant date
- Expiration
- Claims
- 26
- CPC classes
- A61K, A61K31/4704, A61P, A61P11/00
More from Almirall, S.A.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 9108918?
US 9108918 (Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate) is held by Almirall, S.A.. Status: granted. Granted Aug 18, 2015. Expires Aug 13, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9108918?
Almirall, S.A. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 9108918 expire?
Our index shows an expiration date of Aug 13, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.